Evidence map›Paper›PMID 36499754›Full record

ArticleInternational journal of molecular sciences2022

Evaluation of a Novel Oncolytic Adenovirus Silencing

Christie Vermeulen, Tereza Brachtlova, Nikki Tol, Ida H van der Meulen-Muileman, Jasmina Hodzic, Henri J van de Vrugt, Victor W van Beusechem

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Christie VermeulenAmsterdam UMC location Vrije Universiteit Amsterdam, Medical Oncology, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands.ORCID 0000-0003-4575-2874
Tereza BrachtlovaAmsterdam UMC location Vrije Universiteit Amsterdam, Medical Oncology, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands.
Nikki TolAmsterdam UMC location Vrije Universiteit Amsterdam, Medical Oncology, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands.
Ida H van der Meulen-MuilemanAmsterdam UMC location Vrije Universiteit Amsterdam, Medical Oncology, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands.ORCID 0000-0002-3821-9927
Jasmina HodzicAmsterdam UMC location Vrije Universiteit Amsterdam, Medical Oncology, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands.
Henri J van de VrugtCancer Center Amsterdam, Cancer Biology and Immunology, Amsterdam, The Netherlands.
Victor W van BeusechemAmsterdam UMC location Vrije Universiteit Amsterdam, Medical Oncology, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands.
Amsterdam University Medical Centers · NLOncode Institute · NL

Funding

Technology Foundation STW 07710
6 · The paper itself

Abstract

Oncolytic adenoviruses are promising new anticancer agents. To realize their full anticancer potential, they are being engineered to express therapeutic payloads. Tumor suppressor p53 function contributes to oncolytic adenovirus activity. Many cancer cells carry an intact

Indexed as

Oncolytic VirotherapyOncolytic VirusesAdenoviridaeCell Line, TumorHumansTumor Suppressor Protein p53Ubiquitin-Protein LigasesVirus ReplicationXenograft Model Antitumor AssaysSYVN1 protein, humanTumor Suppressor Protein p53Ubiquitin-Protein Ligasescancer-cell-killing potencyoncolytic adenovirusRNA interferenceSYVN1/HRD1/DER3TP53

Identifiers

PMID36499754
PMCPMC9737683
OpenAlexW4311678651

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.